Arovella Therapeutics Limited (ASX:ALA)

Market Cap	124.80M
Revenue (ttm)	3.45M
Net Income (ttm)	-6.26M
Shares Out	1.19B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	421,516
Average Volume	1,283,836
Open	0.0990
Previous Close	0.0980
Day's Range	0.0980 - 0.1050
52-Week Range	0.0680 - 0.2100
Beta	-0.08
RSI	49.70
Earnings Date	Aug 21, 2025

About ATSG

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was form...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 27
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ALA

Financial Performance

In 2024, Arovella Therapeutics's revenue was 1.95 million, an increase of 34.20% compared to the previous year's 1.45 million. Losses were -8.75 million, -14.10% less than in 2023.